The U.S. asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033, growing at a CAGR of 4.5% from 2025 to 2033. The rising number of asthma patients in the U.S. has led to a growing demand for effective therapies, including some of the most advanced and promising treatment options.
The U.S. asthma therapeutics market is experiencing steady growth, driven by a rising number of asthma cases. According to the American Lung Association, over 25 million people in the U.S. are living with asthma, and approximately 5-10% of them have severe asthma, highlighting the urgent need for more effective and targeted treatment options.Although various therapies are available, many patients continue to experience frequent asthma attacks, highlighting the limitations of current medications. In response, pharmaceutical companies invest in developing advanced therapies that offer targeted and more effective solutions.
In February 2023, Amgen and AstraZeneca announced that the U.S. FDA approved TEZSPIRE for patients aged 12 years and older suffering from severe asthma. It has been approved for self-administration in the U.S. with a new prefilled pen. The product is also approved in the U.S., Japan, the EU, and other countries.
The increasing emphasis on precision medicine and patient-specific treatment plans is notably transforming asthma care markedly in the U.S. There is increasing interest in biomarkers and genetic profiling to effectively guide therapy decisions as healthcare shifts toward a more individualized approach. The changing scenario lets doctors spot the true sources of asthma for each patient and then choose the treatments that have the greatest effect. In addition, artificial intelligence and data analytics are being integrated into clinical practice. This integration improves diagnostic accuracy in addition to monitoring treatment. These particular clinical and technological advancements are not only enhancing therapeutic outcomes. Still, they are also creating new opportunities for pharmaceutical innovation, positioning the U.S. asthma therapeutics market for sustained, innovation-driven growth.
This product will be delivered within 2 business days.
The U.S. asthma therapeutics market is experiencing steady growth, driven by a rising number of asthma cases. According to the American Lung Association, over 25 million people in the U.S. are living with asthma, and approximately 5-10% of them have severe asthma, highlighting the urgent need for more effective and targeted treatment options.Although various therapies are available, many patients continue to experience frequent asthma attacks, highlighting the limitations of current medications. In response, pharmaceutical companies invest in developing advanced therapies that offer targeted and more effective solutions.
In February 2023, Amgen and AstraZeneca announced that the U.S. FDA approved TEZSPIRE for patients aged 12 years and older suffering from severe asthma. It has been approved for self-administration in the U.S. with a new prefilled pen. The product is also approved in the U.S., Japan, the EU, and other countries.
The increasing emphasis on precision medicine and patient-specific treatment plans is notably transforming asthma care markedly in the U.S. There is increasing interest in biomarkers and genetic profiling to effectively guide therapy decisions as healthcare shifts toward a more individualized approach. The changing scenario lets doctors spot the true sources of asthma for each patient and then choose the treatments that have the greatest effect. In addition, artificial intelligence and data analytics are being integrated into clinical practice. This integration improves diagnostic accuracy in addition to monitoring treatment. These particular clinical and technological advancements are not only enhancing therapeutic outcomes. Still, they are also creating new opportunities for pharmaceutical innovation, positioning the U.S. asthma therapeutics market for sustained, innovation-driven growth.
U.S. Asthma Therapeutics Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. asthma therapeutics market report based on drug class, device type, product, route of administration.Drug Class Outlook (Revenue, USD Billion, 2021-2033)
- Anti- inflammatory
- Bronchodilators
- Combination therapy
Device Type Outlook (Revenue, USD Billion, 2021-2033)
- Inhalers
- Nebulizers
Product Outlook (Revenue, USD Billion, 2021-2033)
- Dry Powder
- Metered Dose
- Soft Mist
Route of Administration Outlook (Revenue, USD Billion, 2021-2033)
- Oral
- Inhaled
- Intravenous
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Asthma Therapeutics Market Variable Trends & Scope
Chapter 4. U.S. Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis
Chapter 5. U.S. Asthma Therapeutics Market: Device Type Estimates & Trend Analysis
Chapter 6. U.S. Asthma Therapeutics Market: Product Estimates & Trend Analysis
Chapter 7. U.S. Asthma Therapeutics Market: Route of Administration Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this U.S. Asthma Therapeutics market report include:- Teva Pharmaceutical Industries Ltd.
- GSK plc
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Boehringer Ingelheim International GmbH
- Sanofi.
- Koninklijke Philips N.V.
- Covis Pharma
- Pfizer
- Regeneron
- Amgen
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 13 Billion |
| Forecasted Market Value ( USD | $ 19.2 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | United States |
| No. of Companies Mentioned | 13 |
